Introduction

Xanthelasma palpebrarum (XP) is a common benign eyelid condition characterized by yellowish plaques around the eyes, predominantly affecting the medial canthus. With a prevalence of 1.1-4.4% in the general population (varying by geographic region and population studied), xanthelasma represents one of the most frequently encountered periorbital dermatologic presentations. While commonly associated with dyslipidemia, approximately 50% of patients present with entirely normal lipid profiles, complicating the relationship between this cutaneous finding and systemic metabolic disease.

Epidemiology and Clinical Presentation

Xanthelasma typically emerges in the fourth to fifth decade of life, with documented cases ranging from age 15 to 73 years. Women demonstrate higher prevalence (1.1%) compared to men (0.3%), with a notable female-to-male predominance in most series. The lesions appear as soft, yellowish to orange plaques, usually bilateral and symmetric, that may gradually enlarge over time. Patients frequently report cosmetic concerns as their primary motivation for treatment, though some lesions remain stable for extended periods without progression.

Pathophysiology

Xanthelasma results from deposition of lipid-laden macrophages in the superficial reticular dermis, creating characteristic foam cells or xanthoma cells. The underlying mechanism involves compression of capillaries during blinking cycles mediated by the orbicularis oculi muscle, with age-related weakening of the endothelial lining leading to plasma exudation in the subcutaneous eyelid tissue. When lipid content exceeds the macrophage's regulatory capacity, intracellular lipid accumulation transforms macrophages into foam cells containing unesterified cholesterol, cholesteryl esters, and phospholipids.

Histologic examination reveals a perivascular inflammatory infiltrate consisting of both mononucleated and multinucleated foamy histiocytes with lipid-laden cytoplasmic vacuoles. In normolipidemic patients (those without elevated serum lipids), inflammation with increased vascular permeability plays the primary pathogenic role. Conversely, in hyperlipidemic individuals, elevated circulating lipoproteins cause excess lipid to permeate surrounding tissues, facilitating foam cell formation through increased lipoprotein availability and subsequent macrophage metabolism.

Clinical Evaluation and Dyslipidemia Assessment

While xanthelasma appearance typically allows clinical diagnosis, the critical question remains: does the presence of xanthelasma mandate cardiovascular risk assessment? Current evidence presents conflicting data. Meta-analytic evidence demonstrates that patients with XP have significantly higher serum total cholesterol, low-density lipoprotein (LDL), and apolipoprotein B levels, with relatively lower apolipoprotein A1 levels, suggesting increased atherosclerosis risk. However, a recent large 2024 case-control study found lipid profiles similar between xanthelasma patients and controls, with XP not independently associated with dyslipidemia or cardiovascular disease.

Clinical practice recommendations support obtaining a comprehensive fasting lipid panel in all xanthelasma patients to identify those with underlying dyslipidemia, even acknowledging the prevalence of lipid abnormalities ranges from 9.1% to 67.9% depending on study methodology. The presence of xanthelasma may serve as a clinical trigger for lipid screening, particularly in patients with familial hypercholesterolemia or hyperapobetalipoproteinemia, inherited conditions predisposing to extensive xanthoma formation.

Differential Diagnosis

Several benign eyelid conditions may mimic xanthelasma and must be distinguished on clinical grounds. Syringomas present as multiple small, firm, flesh-colored papules typically affecting the lower eyelids and are distinguished by their higher density, smaller size, and lack of yellowish discoloration. Sebaceous hyperplasia appears as solitary or multiple yellowish papules with characteristic central umbilication and greasy appearance. Milia manifest as tiny white to cream-colored cysts containing keratin, easily distinguished by their small size and intraepidermal location. Lipomas, while fatty in nature, typically appear larger and deeper in the subcutaneous tissue. Careful clinical assessment and dermoscopy generally allow distinction without histopathology.

Treatment Modalities

Trichloroacetic Acid (TCA) Chemical Reconstruction: TCA chemical peeling remains widely available and effective for xanthelasma management. TCA 70% and higher concentrations achieve excellent cosmetic outcomes in 100% of treated patients, with reported clearance rates of 70-100% depending on concentration and application technique. However, recurrence rates range from 25-39%, with one prospective study documenting 34.5% recurrence at six-month follow-up. The procedure involves careful application of TCA directly to lesion surfaces with occlusion or occlusive dressing to prevent spread to surrounding tissue. Advantages include minimal cost, no specialized equipment requirement, and relatively quick office procedure completion. Disadvantages include variable recurrence, potential for hypopigmentation or dyspigmentation (more frequent than with laser treatment), temporary edema, and inconsistent depth of tissue destruction.

Carbon Dioxide (CO2) Laser Ablation: Ablative fractional and fully ablative CO2 lasers represent gold-standard treatment modalities with superior recurrence profiles. Clearance rates exceed 99% for grades I-III xanthelasma and reach approximately 95% for grade IV lesions, with recurrence rates of only 6.8% in large series. The CO2 laser selectively ablates lipid-laden tissue through photothermal vaporization of water content in cells, with minimal thermal damage to surrounding dermis. Fractional CO2 laser technology delivers energy through a pixelated pattern, reducing recovery time compared to fully ablative systems. Ultrapulsed CO2 systems allow precise depth control and reduced postoperative edema. Treatment typically requires single session for most lesions, with superior cosmetic results and lower recurrence compared to TCA.

Erbium:YAG (Er:YAG) Laser Ablation: Er:YAG laser ablation offers advantages particularly relevant to periocular treatment. With water absorption approximately 12-fold greater than CO2 lasers, Er:YAG achieves higher ablation efficiency relative to thermal diffusion, making it particularly suitable for delicate periocular structures. Comparative studies demonstrate recurrence rates of 22-24% for Er:YAG, similar to CO2 laser, with potentially reduced risk of postoperative hypopigmentation in darker skin phototypes. Er:YAG laser may be preferred in patients with Fitzpatrick skin types IV-VI due to reduced melanin absorption and thermal injury to adjacent epidermis.

Surgical Excision: Direct surgical excision remains an option for larger, well-demarcated lesions, offering complete histopathologic examination and definitive removal. The technique involves careful surgical dissection to remove the lipid-laden tissue while preserving the delicate periocular structures and lid architecture. Wound closure typically achieves good cosmetic results with minimal scarring given the natural tension lines of the eyelid. Recurrence rates following surgical excision range from 10-25%, comparable to laser resurfacing. Disadvantages include the need for surgical expertise, increased operative time, and potential for visible scarring if closure is suboptimal.

Cryotherapy: Liquid nitrogen cryotherapy represents an older but still viable option for selected lesions. The approach involves controlled freezing of xanthelasma tissue with carefully monitored freeze-thaw cycles to minimize collateral damage. Results are variable, recurrence rates are high (40-60%), and tissue regeneration may be unpredictable, making cryotherapy less favored than contemporary laser or chemical approaches.

Treatment Selection and Recurrence Management

Treatment selection should consider lesion size and depth, patient skin phototype, desired recovery timeline, and cost considerations. CO2 or Er:YAG laser ablation represents optimal first-line therapy for most patients, offering superior clearance rates and lower recurrence (6.8-22%) with excellent cosmetic outcomes. TCA chemical peeling provides a cost-effective alternative with good efficacy but higher recurrence rates (25-39%) and requires careful application to prevent complications. For patients with Fitzpatrick types IV-VI or those concerned about depigmentation risk, Er:YAG laser offers advantages over CO2 laser.

Recurrence occurs in 6.8-60% of patients depending on treatment modality, and represents a realistic expectation that should be communicated to patients preoperatively. Repeat treatment using the same or alternative modality is often successful for recurrent lesions. Some dermatologists advocate for combination approaches (e.g., initial laser ablation followed by TCA to residual lesions) to optimize clearance and minimize recurrence, though controlled comparative trials are limited.

Complications and Adverse Effects

Postoperative complications vary by treatment modality. With chemical peels, dyspigmentation (hyperpigmentation or more commonly hypopigmentation in darker skin types) occurs more frequently than with laser treatment. Temporary edema, erythema, and crusting are expected in the immediate postoperative period. Rare serious complications include full-thickness tissue destruction if TCA is applied excessively or used at inappropriate concentrations.

Laser treatment complications include transient erythema and edema, with lower rates of postoperative pigmentation changes compared to chemical peels. Er:YAG laser carries slightly lower risk of pigmentation changes in darker phototypes. Thermal injury to the delicate periocular structures must be avoided through careful technique and appropriate settings.

References

  • Xanthelasma Palpebrarum - StatPearls - NCBI Bookshelf. Available at: https://www.ncbi.nlm.nih.gov/books/NBK531501/
  • Xanthelasma: Background, Pathophysiology, Epidemiology. Medscape Medical Reference. Available at: https://emedicine.medscape.com/article/1213423-overview
  • Carbon dioxide laser excision as a novel treatment for large xanthelasma palpebrarum: long-term efficacy and safety. Plastic and Reconstructive Surgery - Global Open. PMC. Available at: https://pmc.ncbi.nlm.nih.gov/articles/PMC11866290/
  • A Clinical and Dermatoscopic Perspective of the Efficacy and Safety of Erbium: YAG Laser Ablation Versus 50% Trichloroacetic Acid for the Management of Xanthelasma Palpebrarum. PMC. Available at: https://pmc.ncbi.nlm.nih.gov/articles/PMC11086933/
  • A Practical Review of the Management of Xanthelasma palpebrarum. Plastic and Reconstructive Surgery - Global Open. PMC. Available at: https://pmc.ncbi.nlm.nih.gov/articles/PMC10208694/
  • Serum lipids and risk of atherosclerosis in xanthelasma palpebrarum: A systematic review and meta-analysis. Journal of the American Academy of Dermatology. Available at: https://www.jaad.org/article/S0190-9622(19)32690-8/fulltext
  • Association Between Xanthelasma Palpebrarum with Cardiovascular Risk and Dyslipidemia: A Case Control Study. Ophthalmology. Available at: https://www.aaojournal.org/article/S0161-6420(24)00458-5/abstract
  • Genetic insight into putative causes of xanthelasma palpebrarum: a Mendelian randomization study. Frontiers in Immunology. Available at: https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1347112/full